Earnings call transcript: Georgia Capital Q1 2026 shows robust growth By Investing.com

Georgia Capital delivered a strong Q1 2026 update, with large portfolio company EBITDA up 27% YoY, operating cash flow up 30%, and NAV per share up 9.2% year-to-date in GEL terms despite being flat in the quarter. The retail pharmacy business posted record gross margin of 34% and 20.5% EBITDA growth, while insurance profit rose 70% and the company repurchased 475,000 shares for $22 million. Management reiterated a zero-leverage target, expected 2026 dividend inflows above GEL 200 million, and continued focus on Armenia and selective capital returns.

Analysis

The market is still underappreciating how much of this story is now self-reinforcing. Stronger operating cash flows, declining leverage, and repeated buybacks create a mechanical uplift to NAV/share that is larger than the underlying EBITDA growth alone would suggest; the real kicker is that the discount to NAV is compressing while the company is still buying stock, so every repurchase is becoming incrementally less accretive on the margin but more important as a signal of management conviction. That dynamic should keep the stock supported on any pullback, because the marginal seller is now fighting both fundamentals and an active capital return bid.

The second-order winners are the domestic peers tied to consumer spending and financial intermediation, not just the parent equity. Pharmacy, outpatient healthcare, and insurance are all showing signs of pricing power in a market where inflation is still manageable but wage and service demand are firm; that tends to pressure smaller competitors through either loss of share or forced reinvestment. The bigger geopolitical overlay is that higher oil and Middle East volatility can be a net macro positive for Georgia via trade, transit, and capital inflows, but that also makes the economy more exposed to external sentiment shocks — the growth impulse is real, yet it is still partly exogenous and could fade quickly if regional risk sentiment normalizes.

The main contrarian issue is that the market may be extrapolating too linear a path from one unusually strong quarter. Insurance and pharmacy look less like infinite growth engines and more like businesses whose near-term margins benefited from mix, tariffs, and unusually favorable operating leverage; if pricing or claims normalize, the step-up in profitability can flatten faster than consensus expects. Meanwhile, the deleveraging story is close to completion, which removes one common source of multiple expansion — after zero debt, future upside likely has to come from execution in Armenia/bolt-ons or realized divestments, not just balance-sheet repair.

Key Decisions for Investors

• Long GS (Georgia Capital PLC) on 1-3 month horizon into the next dividend/buyback update: thesis is continued NAV discount compression plus ongoing repurchases; risk/reward favors buying dips rather than chasing strength.
• Pair trade: long GS vs short a basket of smaller regional healthcare/pharmacy operators over 3-6 months. GS has better cash conversion, leverage reduction, and scale-driven pricing power; downside is sector-wide regulatory change, which would hurt both legs.
• Buy medium-dated call spreads on GS for 3-6 months rather than outright stock if you want convexity to a holdco de-leveraging catalyst. Upside is additional rerating if management announces a new capital return program; risk is the stock already prices in a lot of the near-term good news.
• Long selective Georgian consumer/financial proxies if available in the local market or ADR/EM sleeves, with a 6-12 month view. The second-order beneficiary is domestic demand/capital-market sentiment; invalidate if oil-driven geopolitical optimism reverses or the macro impulse stalls.
• Avoid shorting GS on valuation alone unless the discount to NAV narrows materially below current levels and buybacks stop. The stock has a built-in buyer, and shorting into ongoing capital return is poor timing unless you have a clear catalyst for slower operating cash flow.